Ranbaxy Pharmaceuticals Pty Limited Pharmaceutical Import Profile — South Africa (DGFT 2022–2026)

Name: Ranbaxy Pharmaceuticals Pty Limited Pharmaceutical Import Records from India — 5 Products, $6.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ranbaxy Pharmaceuticals Pty Limited — Pharmaceutical Importer Profile (2026) | 5 Products, $6.4M Trade | TransData Nexus

Ranbaxy Pharmaceuticals Pty Limited

Pharmaceutical Importer · South Africa · Medical Devices & Diagnostics Focus · $6.4M Total Trade · DGFT Verified

Ranbaxy Pharmaceuticals Pty Limited is a pharmaceutical importer based in South Africa with a total trade value of $6.4M across 5 products in 5 therapeutic categories. Based on 171 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Ranbaxy Pharmaceuticals Pty Limited sources from 4 verified Indian suppliers, with Sun Pharmaceutical Industries Limited accounting for 87.8% of imports.

Ranbaxy Pharmaceuticals Pty Limited — Import Portfolio & Supplier Network

Ranbaxy Pharmaceuticals Pty Limited import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Ranbaxy Pharmaceuticals Pty Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$4.8M	160	87.8%
Cadila Pharmaceuticals Limited	$424.5K	20	7.7%
Athena Drug Delivery Solutions Private Limited

What Formulations Does Ranbaxy Pharmaceuticals Pty Limited Import?

Formulation	Value	Ships
Nexipraz otc tabs 20MG Each TAB contains: esomeprazole magnesium amorphous eq toesomeprazole 20MG Pack:2x7(s07	$150.0K	3
Lipogen 10MG tabs Each TAB contains atorvastatin calcium eq. to atorvastatin 10MG Pack : box3x10s	$109.9K	3
Nexipraz otc tabs 20MG Each TAB contains: esomeprazole magnesium amorphous eq. to esomeprazole 20MG Pack : 2x7 (s07	$107.1K	3
Vexabax TAB 600/300MG Each TAB containsabacavir sulphate 600MG lamivudine 300MG Pack : 30s	$107.0K	3
Telatri TAB 50/300/300MG Each film coated TAB contains: dolutegravir 50MG lamivudine USP 300MG tenofovir disoproxil	$100.0K	2
Dazit tablets.Each tablet contains : desloratadine tablets 5MG Pack : 30	$100.0K	2
Patram tramadol hydrochloride 37.5MG and paracetamol 325 MG film coated	$100.0K	2
Coricib 60MG tabs Each TAB contains etoricoxib 60MG Pack : 4x7s	$100.0K	3
Alapren TAB 10 MG (enalapril maleate tablets) Each film coated tablet contains:enalapril maleate 10MG Pack : 4x7s	$97.1K	3
Patram tramadol hydrochloride 37.5MG and paracetamol 325 MG film coated tablets qty. 20000 packs x 10 x	$89.8K	2
Caxeta TAB 500MG 120s sa capecitabine tablets 500 mgpack : 12*10 sap code : 1156105 hsn code	$88.3K	2
Tramadol hcl injections dolotram 100MG/2ML Pack	$86.7K	2
Pantocid iv 40MG INJ pantoprazole for	$81.3K	2
Pha drg & med wormstop 100 tablets cont.mebendazole USP qty.	$69.6K	2
Lipogen 40MG tabs Each TAB contains atorvastatin calcium eq. to atorvastatin 40MG Pack : box3x10s	$58.7K	2

Ranbaxy Pharmaceuticals Pty Limited imports 154 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Strip	Medical Devices & Diagnostics	$4.3M	108	2.2%	6
2	Mebendazole	Antimalarial & Antiparasitic	$1.2M	35	4.0%	2
3	Ondansetron	Gastrointestinal	$450.0K	9	0.2%	16
4	Enalapril	Cardiovascular	$312.5K	11	0.1%	17
5	Vildagliptin	Advanced Diabetes Medications	$112.1K	8	1.1%	17

Ranbaxy Pharmaceuticals Pty Limited imports 5 pharmaceutical products across 5 categories into South Africa totaling $6.4M.

Ranbaxy Pharmaceuticals Pty Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Ranbaxy Pharmaceuticals (Pty) Ltd, a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd, is a prominent pharmaceutical importer and distributor based in South Africa. Established in 1996, the company has significantly contributed to the South African healthcare sector by providing a diverse range of generic and over-the-counter (OTC) medications.

The company's headquarters are located at 14 Lautre Road, Stormill Extension 1, Roodepoort, Gauteng, 1724, South Africa. This strategic location facilitates efficient distribution across the country. Ranbaxy Pharmaceuticals (Pty) Ltd operates as a key player in the South African pharmaceutical supply chain, focusing on the importation and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Their product portfolio spans various therapeutic categories, catering to a wide range of medical needs.

2Distribution Network

Ranbaxy Pharmaceuticals (Pty) Ltd maintains a robust distribution network within South Africa, ensuring the widespread availability of its products. The company's state-of-the-art manufacturing facility in Roodepoort produces a comprehensive range of pharmaceutical products, including analgesics, cold, cough, and flu preparations, anti-histamines, anti-hypertensives, central nervous system (CNS) medicines, vitamins, and minerals. These products are distributed to various regions within South Africa and neighboring markets, demonstrating the company's extensive geographic coverage.

3Industry Role

In the South African pharmaceutical supply chain, Ranbaxy Pharmaceuticals (Pty) Ltd functions primarily as a pharmaceutical importer and distributor. The company imports finished pharmaceutical formulations from India, focusing on a diverse range of products across multiple therapeutic categories. By leveraging its manufacturing capabilities and distribution network, Ranbaxy Pharmaceuticals (Pty) Ltd plays a pivotal role in ensuring the availability of essential medications to meet the healthcare needs of the South African population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Ranbaxy Pharmaceuticals Pty Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Ranbaxy Pharmaceuticals (Pty) Ltd exhibits a high degree of sourcing concentration, with 87.8% of its imports originating from Sun Pharmaceutical Industries Ltd, as per the data from 2022 to 2026. This significant reliance on a single supplier indicates a strategic choice to maintain a consistent and reliable supply chain. The stability of this relationship is evidenced by the substantial number of shipments—160 out of 171 total shipments—suggesting a strong and enduring partnership. However, such concentration also presents potential risks, including vulnerability to supply disruptions or changes in supplier dynamics.

2Supply Chain Resilience

The resilience of Ranbaxy Pharmaceuticals (Pty) Ltd's supply chain is closely tied to its dependence on Sun Pharmaceutical Industries Ltd. While this concentrated sourcing strategy ensures consistency and quality, it also exposes the company to risks associated with supply chain disruptions. The limited number of suppliers—four in total—suggests a lack of diversification, which could impact the company's ability to adapt to unforeseen challenges. Additionally, the data indicates that the majority of imports are sourced from a single supplier, further highlighting the need for strategic planning to mitigate potential supply chain vulnerabilities.

Strategic Implications

Importing Pharmaceuticals into South Africa — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for South Africa

1Regulatory Authority & Framework

The South African Health Products Regulatory Authority (SAHPRA) is the primary regulatory body overseeing the importation and distribution of pharmaceutical products in South Africa. SAHPRA operates under the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), which governs the registration, importation, and distribution of medicines and related substances. This legislation ensures that all pharmaceutical products meet the required safety, efficacy, and quality standards before they are made available to the public. (sahpra.org.za)

2Import Licensing & GMP

To import pharmaceutical products into South Africa, companies must obtain an import license from SAHPRA. This license is granted to entities that are registered with SAHPRA and comply with Good Manufacturing Practice (GMP) standards. GMP certification ensures that pharmaceutical products are consistently produced and controlled according to quality standards. Recognized GMP certifications include those from the European Union (EU GMP), the World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Additionally, companies must hold wholesale distribution authorization to distribute pharmaceutical products within South Africa.

Quality & Labeling

Ranbaxy Pharmaceuticals Pty Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Ranbaxy Pharmaceuticals (Pty) Ltd's focus on importing products in the Medical Devices & Diagnostics, Antimalarial & Antiparasitic, and Gastrointestinal therapeutic categories aligns with the pressing healthcare needs in South Africa. The substantial import value in the Medical Devices & Diagnostics category (67.4%) indicates a strategic emphasis on diagnostic tools and medical equipment, which are critical for effective healthcare delivery. The inclusion of Antimalarial & Antiparasitic (18.9%) and Gastrointestinal (7.1%) products reflects the company's commitment to addressing prevalent health issues in the region. This targeted product strategy enables Ranbaxy Pharmaceuticals (Pty) Ltd to meet specific market demands and contribute to the overall health and well-being of the South African population.

2Sourcing Profile

Ranbaxy Pharmaceuticals (Pty) Ltd's sourcing strategy is centered on importing finished pharmaceutical formulations from India, with a significant emphasis on products from Sun Pharmaceutical Industries Ltd. This approach ensures access to a wide range of generic medications that are both cost-effective and of high quality. The company's focus on finished formulations, rather than raw Active Pharmaceutical Ingredients (APIs) or bulk drugs, indicates a preference for ready-to-market products that can be swiftly distributed to meet local demand. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a strategic partner for Ranbaxy Pharmaceuticals (Pty) Ltd in fulfilling the South African market's needs.

Seller's Guide — How to Become a Supplier to Ranbaxy Pharmaceuticals Pty Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Ranbaxy Pharmaceuticals (Pty) Ltd, particularly in therapeutic categories where the company has a significant import value. The existing sourcing pattern, heavily reliant on Sun Pharmaceutical Industries Ltd, presents an opportunity for alternative suppliers to offer complementary products or competitive pricing. Identifying gaps in Ranbaxy Pharmaceuticals (Pty) Ltd's current sourcing, such as specific formulations or dosage forms not currently imported, can provide a strategic entry point for new suppliers. Engaging in direct communication to understand the company's unmet needs and aligning product offerings accordingly can enhance the prospects of establishing a successful partnership.

2Requirements & Qualifications

Indian exporters aiming to supply Ranbaxy Pharmaceuticals (Pty) Ltd and enter the South African market must ensure compliance with SAHPRA's regulatory requirements. This includes obtaining GMP certifications recognized by SAHPRA, such as EU GMP, WHO GMP, or PIC/S. Additionally, exporters must adhere to South African labeling standards, which may require translations into official languages and inclusion of specific product information.

Frequently Asked Questions — Ranbaxy Pharmaceuticals Pty Limited

What products does Ranbaxy Pharmaceuticals Pty Limited import from India?

Ranbaxy Pharmaceuticals Pty Limited imports 5 pharmaceutical products across 5 categories. Top imports: Strip ($4.3M), Mebendazole ($1.2M), Ondansetron ($450.0K), Enalapril ($312.5K), Vildagliptin ($112.1K).

Who supplies pharmaceuticals to Ranbaxy Pharmaceuticals Pty Limited from India?

Ranbaxy Pharmaceuticals Pty Limited sources from 4 verified Indian suppliers. The primary supplier is Sun Pharmaceutical Industries Limited (87.8% of imports, $4.8M).

What is Ranbaxy Pharmaceuticals Pty Limited's total pharmaceutical import value?

Ranbaxy Pharmaceuticals Pty Limited's total pharmaceutical import value from India is $6.4M, based on 171 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Ranbaxy Pharmaceuticals Pty Limited focus on?

Ranbaxy Pharmaceuticals Pty Limited imports across 5 categories. The largest: Medical Devices & Diagnostics (67.4%), Antimalarial & Antiparasitic (18.9%), Gastrointestinal (7.1%).

Get Full Ranbaxy Pharmaceuticals Pty Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 5 company name variants from customs records. For current shipment-level data, contact TransData Nexus.